Skip Navigation


European Heart Journal Advance Access originally published online on May 12, 2006
European Heart Journal 2006 27(11):1264-1265; doi:10.1093/eurheartj/ehl010
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
27/11/1264    most recent
ehl010v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Vogelzang, M.
Right arrow Articles by Zijlstra, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vogelzang, M.
Right arrow Articles by Zijlstra, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Glucose metabolism and acute myocardial infarction

Mathijs Vogelzang* and Felix Zijlstra

Department of Cardiology, Thoraxcenter, University Medical Center Groningen, University of Groningen, PO Box 30 001, 9700 RB Groningen, The Netherlands

* Corresponding author. Tel: +31 50 361 23 55; Fax: +31 50 361 43 91. E-mail address: m.vogelzang@thorax.umcg.nl

This editorial refers to ‘Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the Cardinal study’{dagger} by A. Goyal et al., on page 1289

The first 10% of the full text of this article appears below.

For over 50 years, efforts have been made to develop beneficial glycometabolic support strategies for patients with myocardial ischaemia and infarction.1 The concept of providing maximal metabolic support to injured myocardial cells is elegant, and has led to relatively simple and low-cost interventions. Glucose–insulin–potassium (GIK) therapy focuses on infusion of high doses of glucose to halt free fatty acid production, and various schemes have been studied over the past decades. Clinical results of GIK infusion have been mixed, with results varying from impressive survival benefits to excess mortality. The CREATE-ECLA study, in which 20 201 patients were randomized to GIK infusion or standard treatment after ST-segment elevation myocardial infarction, showed no benefit of GIK infusion (hazard ratio for 30-day mortality, 1.03; 95% CI, 0.95–1.13).2 GIK also showed a neutral effect on secondary endpoints. This . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study
Abhinav Goyal, Kenneth W. Mahaffey, Jyotsna Garg, Jose C. Nicolau, Judith S. Hochman, W. Douglas Weaver, Pierre Theroux, Gustavo B.F. Oliveira, Thomas G. Todaro, Christopher F. Mojcik, Paul W. Armstrong, and Christopher B. Granger
EHJ 2006 27: 1289-1297. [Abstract] [FREE Full Text]